PBYI News and Press, Puma Biotechnology Inc From 01/20/21

The following slide deck was published by Puma Biotechnology, Inc. in conjunction with this event. For further details see: Puma Biotechnology (PBYI) Special Call - Slideshow

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company on January 21, 2021 at the virtual B. Riley Oncology Investor Conference. A re...

Puma Biotechnology (PBYI) announces interim results from the biliary tract cancers cohort of the ongoing SUMMIT trial of neratinib. The Phase II SUMMIT basket trial evaluates the safety and efficacy of neratinib administered daily to patients who have HER2 (ERBB2) mutation-positive advanced b...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced interim results from the biliary tract cancers cohort of the ongoing SUMMIT trial of neratinib at the virtual 2021 Gastrointestinal Cancers Symposium hosted by the American Society of Clinical Oncology (ASCO...

Gainers: [[AAME]] +53.3%. [[BPFH]] +27.8%. [[AIH]] +11.4%. [[ASLN]] +11.2%. [[GRTS]] +10.1%.Losers: [[VRAY]] -11.1%. [[GDS]] -8.4%. [[PBYI]] -5.5%. [[ACY]] -5.4%. [[GBIO]] -5.3%. For further details see: AAME, AIH, GDS and VRAY among after-hours movers

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at the H.C. Wainwright VIRTUAL BioConnect Conference. The presentation will be...

Puma Biotechnology continues to report encouraging clinical data for its flagship product, NERLYNX. Unfortunately, the commercial numbers continue to remain in purgatory. I take a look at the company's recent earnings report to extract some key commercial metrics and trends that have ...

Puma Biotechnology ([[PBYI]] +4.0%) results from its Phase 3 NALA trial show improved central nervous system ((CNS)) outcomes with neratinib-based regimens in the treatment and prevention of CNS metastases from HER2-positive breast cancer.Trial was a randomized controlled trial of neratinib p...

Results show improved CNS outcomes with neratinib-based regimens in the treatment and prevention of CNS metastases from HER2-positive breast cancer Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented efficacy and safety outcomes in a subgroup of p...

Puma Biotechnology (PBYI) jumps 9% after-hours after presenting efficacy results of neratinib in HER2-positive early stage breast cancer (eBC) from the Phase III ExteNET trial at the 2020 Virtual San Antonio Breast Cancer Symposium. The trial included 2,840 patients who received ner...